Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma (Q36356089)

27 February 2018

title

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma (English)

1 reference

27 February 2018

1 reference

7

1 reference

27 February 2018

Pier Luigi Zinzani

2

object named as

Pier Luigi Zinzani

1 reference

27 February 2018

Michelle A Fanale

3

object named as

Michelle A Fanale

1 reference

27 February 2018

Margaret A Shipp

13

object named as

Margaret A Shipp

1 reference

27 February 2018

author name string

Robert Chen

1

1 reference

27 February 2018

Philippe Armand

4

1 reference

27 February 2018

Nathalie A Johnson

5

1 reference

27 February 2018

Pauline Brice

6

1 reference

27 February 2018

Vincent Ribrag

8

1 reference

27 February 2018

Daniel Molin

9

1 reference

27 February 2018

Theodoros P Vassilakopoulos

10

1 reference

27 February 2018

Akihiro Tomita

11

1 reference

27 February 2018

Bastian von Tresckow

12

1 reference

27 February 2018

Yinghua Zhang

14

1 reference

27 February 2018

Alejandro D Ricart

15

1 reference

27 February 2018

Arun Balakumaran

16

1 reference

27 February 2018

Craig H Moskowitz

17

1 reference

27 February 2018

KEYNOTE-087

18

1 reference

27 February 2018

language of work or name

English

0 references

publication date

25 April 2017

1 reference

27 February 2018

Journal of Clinical Oncology

published in

1 reference

27 February 2018

volume

35

1 reference

27 February 2018

issue

19

1 reference

27 February 2018

page(s)

2125-2132

1 reference

27 February 2018

Treatment of relapsed and refractory Hodgkin Lymphoma

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Treatment of advanced-stage Hodgkin lymphoma

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Treatment of early-stage Hodgkin lymphoma

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Hodgkin lymphoma: Pathology and biology

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Standard therapy of advanced Hodgkin lymphoma

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

The biology of Hodgkin's lymphoma

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

How I treat relapsed and refractory Hodgkin lymphoma.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

Revised response criteria for malignant lymphoma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5791843

22 September 2018

Identifiers

DOI

10.1200/JCO.2016.72.1316

1 reference

27 February 2018

PMC publication ID

5791843

1 reference

27 February 2018

PubMed publication ID

28441111

1 reference

27 February 2018